Compare Globus Medical Inc. Class A Common Stock (GMED) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Lennar Corporation — how do they compare? Globus Medical Inc. Class A Common Stock trades at $77.42 (market cap $10.25B), while Lennar Corporation trades at $76.06 (market cap $17.47B). The key difference: Lennar Corporation is the larger of the two by market cap, and Lennar Corporation pays a 2.72% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Lennar Corporation for 67 Days on average.
| GMED | LEN | |
|---|---|---|
Market Cap | $10.25B | $17.47B |
Volume | 1,059,528 | 5,582,939 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $133.13 |
52-Week Low | $58.33 | $73.53 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $9.76B | $21.89B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
LEN trades at $74.92, up 0.36% on the day, with a bearish technical signal from moving averages but oversold RSI levels. The stock is valued below book value (P/B 0.81) and has missed earnings estimates for three consecutive quarters. Recent news highlights Berkshire Hathaway increasing its stake to 11.2%, contrasting with a short report from Hunterbrook Media alleging questionable transactions.
Outlook: LEN offers value with low valuation multiples, but faces headwinds from declining revenue and margins. Risks include housing market sensitivity to interest rates and earnings execution. Analyst consensus is a Buy with a $77.38 target, implying modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
